MTTI presents breakthrough tumor visualization technology at WMIC 2023 in Montreal

Molecular Targeting Technologies, Inc. (MTTI) presented its findings on CypH-11 (Cmetglo), a proprietary near-infrared fluorescent dye, at the World Molecular Imaging Conference (WMIC) in Montreal from September 9-13, 2023. This innovative technology aims to enhance fluorescence-guided surgery (FGS) by allowing surgeons to visualize small tumor residues, thereby improving the completeness of cancer resections in the abdominal cavity. The dye is particularly promising for patients with peritoneal surface malignancies, potentially leading to better patient outcomes and increased progression-free survival rates. Dr. Johnny Ong from the National Cancer Centre Singapore highlighted the challenges of distinguishing tumors from normal tissues during cytoreductive surgery. Preliminary analyses suggest that Cmetglo may be especially beneficial for patients with colorectal malignancies, with potential applications in other cancer types. The technology's ability to make tumor margins visible under near-infrared light could significantly aid surgeons in achieving maximal cytoreduction. CypH-11 is a sprayable, pH-responsive fluorogenic probe that fluoresces in acidic environments, a characteristic associated with cancer cell proliferation. This feature was validated in a model of high-grade serous ovarian cancer, demonstrating its capability to detect small tumors effectively. Chris Pak, MTTI's President & CEO, emphasized the molecule's role in advancing targeted diagnostics and therapeutics across various cancer types. The research is supported by the National Cancer Institute and the Singapore Ministry of Health, reflecting a collaborative effort to enhance cancer treatment methodologies. MTTI's ongoing development of Cmetglo aims to provide significant benefits to patients and healthcare professionals alike.